159 related articles for article (PubMed ID: 6362105)
1. The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. Correlation of skin reactivity and leukocyte migration-inhibition factor in the sera of anergic subjects.
Velardi A; Rambotti P; Cernetti C; Spinozzi F; Bertotto A; Martelli MF
Thymus; 1983 Sep; 5(5-6):429-32. PubMed ID: 6362105
[TBL] [Abstract][Full Text] [Related]
2. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bertotto A; Spinozzi F; Bracaglia AM; Falini B; Davis S
Cancer; 1982 Aug; 50(3):490-7. PubMed ID: 7046903
[TBL] [Abstract][Full Text] [Related]
3. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
[TBL] [Abstract][Full Text] [Related]
4. [Current views on the mechanism of immunological disorders in Hodgkin's disease].
Voĭtenkov BO; Letskiĭ VB; Gavrilenkova LP
Eksp Onkol; 1984; 6(4):17-22. PubMed ID: 6389087
[TBL] [Abstract][Full Text] [Related]
5. [Hodgkin's disease: study of delayed hypersensitivity of 64 non treated patients. Value of epicutaneous test using croton oil].
Goasguen J; Leblay R; Guerin D; Le Prise PY; Richier JL
Sem Hop; 1977 Jan; 53(4):219-25. PubMed ID: 189435
[TBL] [Abstract][Full Text] [Related]
6. Immunological monitoring in lung cancer: use of the leukocyte migration inhibition assay.
Abai AM; Fekete B
Haematologia (Budap); 1982; 15(1):111-25. PubMed ID: 6749608
[TBL] [Abstract][Full Text] [Related]
7. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
Levo Y; Rotter V; Ramot B
Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
[TBL] [Abstract][Full Text] [Related]
8. In vitro evidence of normal lymphocyte function in some patients with Hodgkin's disease and negative delayed cutaneous hypersensitivity.
Churchill WH; Rocklin RR; Moloney WC; David JR
Natl Cancer Inst Monogr; 1973 May; 36():99-106. PubMed ID: 4583000
[No Abstract] [Full Text] [Related]
9. Cellular hypersensitivity to tuberculin in BCG-revaccinated persons studied by skin reactivity, leucocyte migration inhibition and lymphocyte proliferation.
Repo H; Kostiala AA; Kosunen TU
Clin Exp Immunol; 1980 Feb; 39(2):442-8. PubMed ID: 6993072
[TBL] [Abstract][Full Text] [Related]
10. Effect of transfer factor on lymphocyte function in anergic patients.
Kirkpatrick CH; Rich RR; Smith TK
J Clin Invest; 1972 Nov; 51(11):2948-58. PubMed ID: 5080419
[TBL] [Abstract][Full Text] [Related]
11. In vitro reversal of cellular unresponsiveness induced by levamisole.
Golding H; Golding B; Jacobson R; Lomnitzer R; Koornhof HJ; Rabson AR
Clin Exp Immunol; 1976 Nov; 26(2):295-301. PubMed ID: 791550
[TBL] [Abstract][Full Text] [Related]
12. Influence of thymosterin on immunological reactivity in New Zealand mice.
Rovenský J; Pekárek J; Cebecauer L; Zitnan D; Svejcar J
Folia Biol (Praha); 1976; 22(4):281-4. PubMed ID: 786753
[TBL] [Abstract][Full Text] [Related]
13. Transfer factor therapy for histoplasmosis in a patient with Hodgkin's disease.
Catanzaro A; Spitler LE; Campbell GD; Moser KM
Arch Intern Med; 1981 Mar; 141(4):533-7. PubMed ID: 7212899
[TBL] [Abstract][Full Text] [Related]
14. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
15. Applicability of the leukocyte migration inhibition test in the clinical practice.
Stanciu L; Dumitrescu D; Radu D
Med Interne; 1990; 28(4):295-303. PubMed ID: 2100874
[TBL] [Abstract][Full Text] [Related]
16. Delayed cutaneous hypersensitivity and blood lymphocyte count in advanced Hodgkin's and non-Hodgkin's lymphomas.
Gupta S; Seth SK; Udupa KN; Sen PC; Rastogi BL
Ann Chir Gynaecol; 1980; 69(2):79-83. PubMed ID: 7377739
[TBL] [Abstract][Full Text] [Related]
17. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. I. Hodgkin's disease. (Correlation with immunity response of the cellular type and with the clinical status).
Libánský J; Lukásová M; Pinosová I
Neoplasma; 1973; 20(1):51-60. PubMed ID: 4702205
[No Abstract] [Full Text] [Related]
18. Influence of the thymic extract (TP2) on some humoral and cell mediated immunity reactions in normal or irradiated animals.
Boeru V; Briese MA; Olariu M
Endocrinologie; 1983; 21(4):233-41. PubMed ID: 6364318
[TBL] [Abstract][Full Text] [Related]
19. The in vitro effect of a calf thymus extract (thymostimulin) on the immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bracaglia AM; Ballatori E; Davis S
Cancer; 1982 Jan; 49(2):245-50. PubMed ID: 7053826
[TBL] [Abstract][Full Text] [Related]
20. Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.
Liberati AM; Brugia M; Edwards BS; Bertoni P; Ballatori E; Puxeddu A; Grignani F
Cancer Immunol Immunother; 1985; 19(2):136-41. PubMed ID: 3872709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
